129Xenon MR Imaging and Spectroscopy Response to Sotatercept in Pulmonary Arterial Hypertension
Determine the ability of 129Xe MRI/MRS biomarker signatures to non-invasively monitor pulmonary vascular reverse remodeling induced by sotatercept in pulmonary arterial hypertension (PAH).
• Outpatients of either gender, Age 18-75
• Diagnosis of precapillary PH (right heart catheterization demonstrating hemodynamic criteria of a mean pulmonary artery pressure (mPAP) ≥ 20 mmHg, pulmonary vascular resistance ≥ 5 WU, pulmonary capillary wedge pressure ≤ 15 mmHg) in the setting of Group 1 (PAH)
• Willing and giving informed consent and adhere to visit/protocol schedules (consent must be given before any study procedures are performed).
• On a stable dose of background PAH therapy for \> 90 days prior to study enrollment
• Women of childbearing potential must have a negative urine pregnancy test before MRI